Oncotarget

Research Papers:

Significance of mesothelin expression in preoperative endoscopic biopsy specimens for colorectal cancer prognosis

Takehiro Shiraishi, Eiji Shinto _, Masato Yamadera, Ken Nagata, Hitoshi Tsuda, Satsuki Mochizuki, Yoshiki Kajiwara, Koichi Okamoto, Takahiro Einama, Yoji Kishi and Hideki Ueno

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release

Oncotarget. 2020; 11:3807-3817. https://doi.org/10.18632/oncotarget.27774

Metrics: PDF 787 views  |   Full Text 943 views  |   ?  


Abstract

Takehiro Shiraishi1, Eiji Shinto1, Masato Yamadera1, Ken Nagata1, Hitoshi Tsuda2, Satsuki Mochizuki1, Yoshiki Kajiwara1, Koichi Okamoto1, Takahiro Einama1, Yoji Kishi1 and Hideki Ueno1

1 Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359-0042, Japan

2 Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359-0042, Japan

Correspondence to:

Eiji Shinto,email: [email protected]

Keywords: colorectal cancer; mesothelin; endoscopic biopsy specimen; immunohistochemistry; Pathology

Abbreviations: CI: confidence interval; DSS: disease-specific survival; TTR: time to recurrence; HR: hazard ratio; ROC: receiver operating characteristic

Received: July 09, 2020     Accepted: September 29, 2020     Published: PUBLISHED_DATE

Copyright: © 2020 Shiraishi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Mesothelin (MSLN) is a cell surface glycoprotein that is normally expressed in the mesothelial cells but highly expressed in several malignant tumors, where the high expression is generally associated with poor prognosis. In this work, 512 patients with stage III colorectal cancer (CRC) were examined to ascertain the prognostic value of MSLN expression in preoperative endoscopic biopsy specimens. MSLN expression was evaluated by immunohistochemical staining. The tumor cells were MSLN-positive in 61 of the 512 patients (11.9%). MSLN expression was associated with a shorter disease-specific survival (DSS) period (5-year DSS = 68.7%, P = 0.0008). Besides, by multivariate analysis, MSLN expression was identified to be a marker of poor prognosis by multivariate analysis (P = 0.0033, hazard ratio (HR) = 2.31) as well as macroscopic type (P = 0.047, HR = 1.82) among the factors that can be evaluated preoperatively. MSLN-positive patients had a significantly poorer prognosis regardless of adjuvant chemotherapy administration (P = 0.0081 and P = 0.0018 for surgery alone and chemotherapy, respectively). MSLN-positive patients in the adjuvant chemotherapy group exhibited a significantly lower risk of recurrence when compared with those in the surgery alone group (P = 0.0090). In conclusion, high MSLN expression observed in preoperative endoscopic biopsy specimens of stage III CRC was an independent poor prognostic factor. Preoperative evaluation of MSLN by immunohistochemical staining might be applied to select individuals for intensive preoperative chemotherapy among the stage III CRC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27774